Table 1.

The results of the intestinal permeability markers at baseline (T0) and after the intervention (T1). Quantitative variables with a normal distribution were expressed as mean ± SD, quantitative variables which showed a non-normal distribution were expressed as median (P25–P75).

	T0			T1
	T0: Placebo Group	T0: Synergy 1 Group	p-Value	T1: Placebo Group	T1: Synergy 1 Group	p-Value	p-Value Placebo T0 vs. T1	p-Value Synergy 1 T0 vs. T1
iFABP 1 [ng/mL]	2.17 ± 0.94	1.98 ± 0.74	0.59	1.03 ± 0.31	1.35 ± 0.64	0.15	<0.001	0.01
Zonulin [ng/mL]	17.38 (12.82–36.72)	28.66 (2.77–38.64)	0.60	28.82 (18.66–40.77)	36.26 (10.12–44.17)	0.69	<0.01	<0.01
GLP-2 2 [ng/mL]	3.17 (2.44–4.22)	2.23 (1.75-3.67)	0.49	3.99 (3.52–4.51)	3.04 (1.78–3.84)	0.10	0.21	0.81
Claudin-3 [ng/mL]	2.75 ± 0.79	2.41 ± 1.03	0.40	2.44 ± 0.67	2.20 ± 0.63	0.38	0.09	0.46
Calprotectin [µg/mg]	32.95 (18.73–81.72)	30.92 (16.47–136.49)	0.69	44.20 (16.00–108.60)	63.73 (34.24–105.37)	0.64	0.33	0.97

¹ intestinal Fatty Acid Binding Protein; ² Glucagon-Like Peptide 2.